Filing Flows › Tango Therapeutics (TNGX) › Q3 2025 › vs Q3 2024
Tango Therapeutics (TNGX) Q3 2025 vs Q3 2024 (year over year)
Tango Therapeutics's revenue rose $42.2M (+364%) from $11.6M in Q3 2024 to $53.8M in Q3 2025. Operating margin 26.2% against -283.3% (+309.4 pts).
Tango Therapeutics, Q3 2025: revenue $53.8M (+364% year over year), operating margin 26.2%, net earnings $15.9M, operating cash flow −$31.0M. The chart draws each line against Q3 2024, the increases inside each band.
Margins
| Q3 2025 | Q3 2024 | Change | |
|---|---|---|---|
| Operating margin | 26.2% | -283.3% | +309.4 pts |
| Net margin | 29.5% | -251.3% | +280.8 pts |
Every line
| Line | Q3 2025 | Q3 2024 | Change | % |
|---|---|---|---|---|
| Revenue | $53.8M | $11.6M | $42.2M | +364% |
| Other income, net | $1.8M | $3.8M | −$2.0M | -52% |
| Operating profit | $14.1M | −$32.9M | $47.0M | — |
| Costs & expenses | $39.7M | $44.5M | −$4.7M | -11% |
| Pre-tax earnings | $15.9M | −$29.1M | $45.0M | — |
| Research & development | $30.8M | $33.3M | −$2.4M | -7% |
| General & admin | $8.9M | $11.2M | −$2.3M | -20% |
| Income tax benefit | $10K | −$54K | $64K | — |
| Net earnings | $15.9M | −$29.2M | $45.1M | — |
| Operating cash sources | $54.0M | $12.0M | $42.0M | +349% |
| Depreciation | $555K | $622K | −$67K | -11% |
| Share-based compensation | $6.6M | $7.2M | −$553K | -8% |
| Cash used in operations | $31.0M | $33.4M | −$2.4M | -7% |
| Working capital & other | $54.0M | $12.0M | $42.0M | +349% |
Questions
How much did Tango Therapeutics's revenue grow year over year in Q3 2025?
Tango Therapeutics's revenue rose $42.2M (+364%) from $11.6M in Q3 2024 to $53.8M in Q3 2025. Operating margin 26.2% against -283.3% (+309.4 pts).